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Background: Hypertension is commonly reported in multiple myeloma (MM) patients and may be associated
with older age, disease-related complications and consequences of MM treatments. This study evaluated the
incidence rates of and risk factors for hypertension and malignant hypertension in newly-treated MM patients
in the United States.
Methods: Newly-treated adult MM patients were identified from Truven MarketScan claims database from 1/1/05
to 3/31/14. Inclusion criteria were new diagnosis of MM with start of MM treatment, ≥12 months continuous
enrollment prior to diagnosis, ≥30 days of continuous enrollment following initial diagnosis, and prescription
drug coverage. Non-MM patients were matched for age (within +/− 5 years), sex and distribution of index dates
to MM patients. Baseline cardiovascular (CV) comorbidities, incidence rate of hypertension and malignant hypertension
in the follow-up period, and risk of hypertension and malignant hypertension based on existing baseline CV
comorbidities were evaluated.
Results: A total of 7895 MM patients (38% with hypertension history) and 23,685 non-MM patients (24% with
hypertension history) were included in the study. Twenty-two percent of MM patients versus 3% of non-MM
patients had baseline renal failure. A higher percentage of MM versus non-MM patients had baseline hypertension
in combination with renal failure, congestive heart failure or both. The incidence rate of hypertension in MM and
non-MM patients was 260 and 178 per 1000 person-years, respectively. There was a 30% increase in the risk of
hypertension for MM versus non-MM patients: hazard ratio (HR) 1.30 (95% confidence interval [CI] 1.22, 1.37). In
MM patients with a history of hypertension, the risk of malignant hypertension was significantly increased with
the following comorbid conditions: cardiomyopathy, HR 2.79 (95% CI 1.20, 6.48); renal failure, HR 2.13 (95% CI 1.36, 3.34);
and diabetes mellitus, HR 1.59 (95% CI 1.05, 2.39).
Conclusions: This study confirms that the incidence of hypertension and malignant hypertension is significantly higher in
newly-treated MM versus non-MM patients. Hypertension is a risk factor for MM patients developing malignant
hypertension. Management of CV comorbidities in MM patients is important based on the increased risk of
hypertension and malignant hypertension among patients with these comorbidities.
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Multiple myeloma (MM) is a bone marrow cancer char-
acterized by clonal plasma cells that may lead to anemia,
hypercalcemia, renal insufficiency and bone destruction
[1]. It is estimated that 30,330 individuals in the United
States (US) will be newly diagnosed with MM in 2016,
the majority of whom are elderly (50% aged ≥69 years of
age) [2]. Even without MM, the elderly population are at
an increased risk for development of cardiovascular
(CV)-related comorbidities, including hypertension [3].
Given the mean age at diagnosis, complications of MM
(eg, bone pain, renal impairment) and frequent use of
corticosteroids (with associated weight gain and anxiety),
hypertension and malignant hypertension events are
likely to occur in patients undergoing therapy for MM.
Epidemiological data on incidence of hypertension in
the general population are available; however, very little
is currently published on the incidence rates of hyper-
tensive crisis and malignant hypertension in oncology
populations, including patients with MM. Taking into
consideration patients with MM are often elderly and
likely to have pre-existing CV comorbidities and poly-
pharmacy, evaluating the risk factors for hypertension
would better enable CV risk management in these pa-
tients. This study evaluates the incidence rates of and
risk factors for hypertension and malignant hypertension
in newly-treated MM patients in the US.
Methods
Data source
This retrospective cohort study utilized data from the
Truven MarketScan claims database. This database is
representative of healthcare received, including treat-
ment patterns and costs of treatment in more than 36
million privately insured patients across the US. It is a
fully integrated, patient-level database containing inpatient,
outpatient, drug, laboratory, health risk assessment and
benefit design information from patients with commercial
and Medicare supplemental insurance. MarketScan is com-
pliant with the Healthcare Information Portability and
Accountability Act (HIPAA).
Study population
The study population consisted of newly-treated patients
with MM identified from the Truven MarketScan data-
base between January 1, 2005 and March 31, 2014 using
the International Classification of Diseases, Revision 9
(ICD-9) codes 203.0, 203.00, 203.01 or 203.02. Patients
were included if they were at least 18 years of age and
had newly diagnosed MM (one inpatient or two out-
patient claims required) with start of MM treatment,
≥12 months of continuous enrollment prior to the first
date of MM diagnosis, ≥30 days of continuous enroll-
ment following initial diagnosis, and prescription drugcoverage. To exclude monoclonal gammopathy of un-
determined significance and asymptomatic myeloma
classified as MM, all patients had to be receiving at least
one MM drug identified on prescription claims. Patients
were excluded if they had another cancer diagnosis
within 12 months prior to, or 12 months following the
initial MM diagnosis, and received prior chemotherapy.
A non-MM comparator cohort was identified from the
original database which included all claims for the MM
cohort. Three randomly selected comparator patients
with no MM diagnoses between January 1, 2005 and
March 31, 2014 were identified for each of the MM pa-
tients so the distribution of index dates for the compara-
tors would match those of the MM patients. Non-MM
patients were also matched to MM patients on age
(within ±5 years of the MM patient’s age at index date)
and sex. Non-MM patients included in the study were at
least 18 years of age, had continuous enrollment during
a 12-month baseline plus at least 1-day follow-up time
period, and had annual prescription drug coverage dur-
ing the year (s) included in the 12 months baseline plus
at least 1-day follow-up time period. The only exclusion
criteria for non-MM patients was having MM; other
non-MM cancers were allowed.Study definitions
The index date for MM patients was the date of first
treatment claim for MM treatment. The index date for
non-MM comparator patients was matched to individuals
in the MM group with 365 days of continuous enrollment
prior to that date. Baseline was defined as the 365 days of
continuous enrollment preceding the index date. Follow-
up was defined as the period from index date to first
occurrence of an event (first diagnostic code) for those
experiencing an event, and was defined as the period from
index date to end of enrollment or end of study time
period (March 2014) for event-free patients.Objectives and study measures
The main objective of this study was to estimate inci-
dence rates of hypertension and malignant hypertension
in a representative sample of treated MM patients and
non-MM comparator patients in the US. Comparison of
hypertensive and malignant hypertensive incidence rates
between treated MM patients and non-MM patients, as
well as to evaluate the risk of hypertension or malignant
hypertension over the follow-up period based on existing
hypertension and other baseline CV comorbidities using
Cox proportional hazards methods. In addition, the total
number of classes of anti-hypertensive medications pre-
scribed at baseline were compared between MM patients
and non-MM patients.
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Patient demographics included age, sex, geographic region
and calendar year of index date. Hypertensive events were
identified from the database using one inpatient or out-
patient claim with an ICD-9 code of 401.××, 402.××,
403.××, 404.××, 405.×× or 437.2×. Patients with prior his-
tory of hypertension were defined as having a hypertensive
event in the baseline period. Other comorbidities included
cardiac dysrhythmias, cardiomyopathy, congestive heart
failure, ischemic heart disease (acute myocardial infarction
and angina), acute myocardial infarction, cerebrovascular
disease (hospitalized stroke and transient cerebral ische-
mia), renal failure, diabetes mellitus, amyloidosis and
hyperlipidemia. All comorbidities were identified using
one inpatient or outpatient claim (ICD-9 codes; see Addi-
tional file 1 Table S1), with the exception of cerebrovascu-
lar disease, which was identified using inpatient claims
only. The Charlson comorbidity index (CCI) was calcu-
lated according to the Quan adaptation [4]. Baseline anti-
hypertensive medications by drug class for treatment of
hypertension were identified and included diuretics,
angiotensin-converting enzyme inhibitors (ACE-I), angio-
tensin II blockers, calcium channel blockers and other
(alpha blockers, alpha-2 receptor agonists, beta blockers,
central agonists, combined alpha and beta blockers, per-
ipheral adrenergic inhibitors, renin inhibitors and vasodi-
lators). Baseline anti-hypertensive medications were
defined as treatments prescribed in the 3 months before
the index date.
Follow-up period measures
The hypertensive events were identified as described for
the baseline period. Malignant hypertensive events were
identified using one inpatient claim with an ICD-9 code
of 437.2×, 401.0×, 402.0×, 403.0×, 404.0× or 405.0×. The
addition of anti-hypertensive medications in the follow-
up period was compared between MM patient and non-
MM patients. For patients with incident hypertension,
anti-hypertensive medications were defined as drugs pre-
scribed after hypertension diagnosis.
Statistical analyses
Incidence rates were estimated using traditional methods
and presented per 1000 person-years (PYRs) with a 95%
confidence interval (CI) of any event. A patient was
counted in the numerator of the incidence rate at the
time of the first diagnostic code for the event in the
follow-up period. The risk of hypertension and malig-
nant hypertension (overall and in patients with and
without a prior hypertensive event) in the MM and non-
MM patients was compared using the Cox proportional
hazards regression model. Univariate Cox models were
first conducted to assess whether individual baseline var-
iables predicted hypertension or malignant hypertension.Multivariate Cox models were then applied. Age, sex
and geographic region were locked into the model and
stepwise methods were used to determine which base-
line comorbidities to include in the model. Analyses
were conducted using SAS® 9.3 (SAS Institute Inc., Cary,
NC, USA). Where appropriate, significance was assessed
at the p < 0.05 level.
Results
A total of 49,565 patients with a MM diagnosis code
claim were identified between January 1, 2005 and
March 31, 2014 (Fig. 1). Based on inclusion and exclu-
sion criteria, 7895 patients were included in the MM
patient cohort for study analysis. A total of 23,685
patients were identified and matched to the MM pa-
tients and comprised the non-MM patient cohort for
study analysis. The MM and non-MM patients were
generally well-matched on distribution of index dates
(Table 1).
The baseline demographics and characteristics for
MM patients and non-MM patients are shown in
Table 1. Both cohorts were equally matched for sex
(55.7% males) and age, with median age (range) at index
date of 64 (18–97) years. A total of 49% of patients were
45–64 years of age and 47% were ≥65 years of age (47%);
less than 4% were <45 years of age. The median duration
of follow-up for both the MM and non-MM patients
was 2 years. The percentage of MM patients with base-
line CV comorbidities was higher than that among non-
MM patients for each of the comorbidities evaluated
(Table 1). Hypertension was the most common comor-
bidity in both groups, with 38% of the MM patients
(3002/7895) having hypertension at baseline compared
with 24% of the non-MM patients (5750/23,685). Heart
failure at baseline was observed in 6.7% (526/7895) and
2.3% (549/23,685) of patients in the MM and non-MM
cohorts, respectively. The largest numeric difference
between MM and non-MM patients was for presence
of baseline renal failure: 22% of MM patients com-
pared with 3% of non-MM patients. A total of 13.1%
(1034/7895) of MM patients had both hypertension
and acute renal failure at baseline compared with 2.1%
(494/23,685) of non-MM patients. A total of 4.1% of
MM patients had both hypertension and congestive
heart failure at baseline versus 1.4% of non-MM pa-
tients. The percentage of patients having hypertension,
renal failure and congestive heart failure at baseline
was 2.3% for MM patients and 0.5% for non-MM pa-
tients. Ischemic heart disease, diabetes mellitus and
hyperlipidemia were present at baseline in 11%–18% of
MM patients, with corresponding rates for non-MM
patients ranging from 8%–16%. Median CCI was 1
(range, 0–12) for the MM patients and 0 (range, 0–15)
for the non-MM patients.
Fig. 1 Selection of MM patient cohort. MM drugs identified on prescription claims. CE, continuous enrollment; ICD-9, international classification of
diseases, ninth revision; MM, multiple myeloma
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The incidence rate of hypertension per 1000 PYRs in
patients with MM was 260 (95% CI 248, 272) and in
non-MM patients was 178 (95% CI 173, 182) (Fig. 2).
Hypertension incidence rates per 1000 PYRs (95% CI) in
MM and non-MM patients by baseline comorbidities
are shown in (Fig. 2).Malignant hypertension in follow-up period
The incidence rate per 1000 PYRs (95% CI) of malignant
hypertension in MM-treated patients without a history
of hypertension was 3.3 (95% CI 2.3, 4.5) and in non-
MM patients without a history of hypertension was 1.9
(95% CI 1.5, 2.3). In patients with a prior history of
hypertension, the incidence rate per 1000 PYRs (95% CI)
for malignant hypertension in MM-treated patients was
10.3 (95% CI 7.8, 13.2) and in non-MM patients was 4.3(95% CI 3.2, 5.5). Rates by baseline comorbidities are
shown in (Fig. 3).
Risk of hypertension or malignant hypertension: Cox
proportional hazards modeling
Adjusted hazard ratios (HRs) for hypertension events
from the multivariate Cox proportional hazards modeling
are presented in Table 2. There was a 30% increase in the
risk of hypertension in MM versus non-MM patients. In
patients with baseline ischemic heart disease, renal failure,
diabetes or hyperlipidemia, the risk of incident hyper-
tension was significantly increased compared with pa-
tients who did not have these comorbidities at baseline
(p < 0.001 for all comparisons; Table 2). Older age
(≥55 years) also increased the risk of incident hyperten-
sion. MM-treated patients with or without a history of
hypertension had a significantly higher risk of malignant
hypertension during the follow-up period compared with
Table 1 Baseline demographics and characteristics




Duration of follow-up, years
Median (range) 2 (0–9) 2 (0–10)
Age at index date, years
Mean ± SD 65.3 ± 11.8 65.3 ± 11.8
Median (range) 64 (18–97) 64 (18–97)
Age, years, n (%)
18–34 26 (0.3) 78 (0.3)
35–44 239 (3.0) 717 (3.0)
45–54 1130 (14.3) 3390 (14.3)
55–64 2747 (34.8) 8241 (34.8)
65–74 1812 (23.0) 5436 (23.0)
75+ 1941 (24.6) 5823 (24.6)
Sex, n (%)
Male 4400 (55.7) 13,200 (55.7)
Female 3495 (44.3) 10,485 (44.3)
Year of index date, n (%)
2005 634 (8.0) 1591 (6.7)
2006 639 (8.1) 1464 (6.2)
2007 607 (7.7) 1492 (6.3)
2008 892 (11.3) 2154 (9.1)
2009 1136 (14.4) 3193 (13.5)
2010 832 (10.5) 2445 (10.3)
2011 1007 (12.8) 3644 (15.4)
2012 1102 (14.0) 4177 (17.6)
2013 908 (11.5) 3039 (12.8)
2014 138 (1.7) 486 (2.1)
Comorbidities at baseline, n (%)
Hypertension 3002 (38.0) 5750 (24.3)
Renal failure 1698 (21.5) 696 (2.9)
Hyperlipidemia 1399 (17.7) 3712 (15.7)
Diabetes mellitus 1242 (15.7) 3007 (12.7)
Ischemic heart disease 841 (10.7) 1777 (7.5)
Cardiac dysrhythmias 563 (7.1) 1019 (4.3)
Congestive heart failure 526 (6.7) 549 (2.3)
Cardiomyopathy 168 (2.1) 176 (0.7)
Amyloidosis 110 (1.4) 3 (0.01)
Acute myocardial infarction 106 (1.3) 133 (0.6)
Cerebrovascular diseasea 100 (1.3) 159 (0.7)
Hypertension + renal failure 1034 (13.1) 494 (2.1)
Hypertension + congestive
heart failure
322 (4.1) 320 (1.4)
Hypertension + renal failure +
congestive heart failure
179 (2.3) 116 (0.5)
Table 1 Baseline demographics and characteristics (Continued)
CCI
Mean ± SD 1.44 ± 1.93 0.41 ± 1.01
Median (range) 1 (0–12) 0 (0–15)
CCI: Charlson comorbidity index, MM: multiple myeloma, SD: standard
deviation
aBased on inpatient claim only
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1.90, 95% CI 1.26, 2.87, p < 0.01; no prior history of hyper-
tension: HR 1.54, 95% CI 1.04, 2.28, p < 0.05). In patients
with a prior history of hypertension, presence of cardio-
myopathy, renal failure or diabetes at baseline significantly
increased the risk of malignant hypertension compared
with absence of these comorbidities at baseline (p < 0.05
all comparisons). In patients without a prior history of
hypertension, only age ≥65 years versus 18–54 years and
mild or high CCI versus low CCI at baseline was associ-
ated with an increased risk of malignant hypertension in
the follow-up period (p < 0.05 all comparisons).
Anti-hypertensive medications in MM and non-MM
patients
The numbers of MM and non-MM patients taking anti-
hypertensive medications at baseline are shown in
Table 3. The proportion of patients receiving at least one
class of anti-hypertensive medication at baseline was the
same for MM and non-MM patients (71%). The number
of classes of anti-hypertensive medication at baseline be-
tween the two groups was similar (Fig. 3). Among patients
who were treated for hypertension, the most common
medications at baseline for both groups were diuretics,
ACE-I, calcium channel blockers and angiotensin II recep-
tor blockers (ARBs) (Table 3). For patients with incident
hypertension, 1425 of 1865 (76.4%) MM patients and
4548 of 5861 (77.6%) non-MM patients received at least
one class of anti-hypertensive medication during follow-
up. A total of 16.0% of MM patients and 10.4% of non-
MM patients received one new class of anti-hypertensive
medication during the follow-up period; 9.9% of MM pa-
tients and 11.2% of non-MM patients received two addi-
tional classes of anti-hypertensive medications during the
follow-up period (Fig. 4).
Discussion
Hypertension is commonly reported in patients with
MM in clinical trials and may be associated with older
age, disease-related complications or consequence of
MM treatments [5–7]. However, little is known about
the incidence of hypertension or malignant hypertension
in the broader population of patients outside of clinical
trials. To our knowledge, this is the first study to esti-
mate the incident rates of hypertension and malignant
Fig. 2 Incidence rate of hypertension (per 1000 PYRs) and 95% confidence intervals. MM, multiple myeloma; PYRs, person-years
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treated patients in the US not participating in clinical
trials compared with age- and gender-matched non-MM
patients. There is a recent study by Kistler and col-
leagues that reported incidence rates of hypertension in
combination with arterial events as part of their evalu-
ation of cardiac events in MM and non-MM patients
based on MarketScan data [8]. They found no significant
difference in risk of hypertension/arterial events between
MM and non-MM patients. This differs from the results
of this current study which found a 30% higher risk of
hypertension in MM patients versus non-MM patients.There were a couple of significant differences in study
design between the two studies. Kistler et al. did not spe-
cifically study hypertension events alone; they evaluated
the incidence of hypertensive and arterial events com-
bined. In addition, the MM patients in the Kistler study
had a longer duration of MM disease, as the inclusion
criteria for the MM cohort required patients to have had
at least three anti-myeloma treatments (thereby introdu-
cing confounding medical issues such as autonomic or
adrenal insufficiency, weight loss, etc.), whereas the
current study included newly-diagnosed MM patients
with at least one anti-myeloma treatment.
Fig. 3 Number of classes of anti-hypertensive medications at baseline for MM and non-MM patients. Anti-hypertensive medications by class included
diuretics, ACE-I, angiotensin II blockers, calcium channel blockers and others (alpha blockers, alpha-2 receptor agonists, beta-blockers, central agonists,
combined alpha and beta blockers, peripheral adrenergic inhibitors, renin inhibitors and vasodilators). ACE-I, angiotension-converting enzyme inhibitor;
MM, multiple myeloma
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non-MM patients (33% of patients) is comparable with
published data for the US adult population (1 out of 3
adults) [9, 10]. That said, the incidence of hypertension
and malignant hypertension is significantly higher in
newly-treated MM patients compared with non-MM pa-
tients. Multi-variate analyses showed that patients with
MM had a statistically significant increased risk of
hypertension compared with non-MM patients and alsoTable 2 Multivariable Cox proportional hazards model:
Predictors of hypertension































CCI (reference: low [0]) Mild (1,2) 1.11
(1.03, 1.20)
<0.01
CCI Charlson comorbidity index, HR hazard ratio, MM multiple myelomaa significantly increased risk of malignant hypertension
in both MM patients with or without a history of hyper-
tension compared with non-MM patients. Whether the
increased risks of hypertension and malignant hyperten-
sion found for MM patients were due to disease-unrelated
factors, disease-related comorbidities or a combination of
these factors is difficult to determine. Older age and male
gender pre-disposes MM patients to an increased risk of
hypertension; however, this study controlled for both these
factors by using age- and sex-matched non-MM patients.
Results of multi-variable modeling found that the
presence of several CV comorbidities increased the risk
of hypertension and malignant hypertension in MM pa-
tients. In patients without a prior history of hyperten-
sion, co-existing ischemic heart disease, renal failure,
diabetes and hyperlipidemia increased the risk of hyper-
tension. In patients with a prior history of hypertension,
co-existing cardiomyopathy, renal failure or diabetes
greatly increased the risk of malignant hypertension.
The presence of all of these co-morbidities was signifi-
cantly higher in the MM population than in the non-
MM population at baseline. High levels of CV comor-
bidities in MM patients have been noted in another
non-clinical study of newly-diagnosed MM patients.
Chen et al. reported that close to half (47.9%) of all
newly-diagnosed MM patients (N = 8239) identified
from commercial medical and Medicare claims data-
bases had more than one type of comorbidity at base-
line (6 months prior to MM diagnosis), with 43.9% of
patients having metabolic comorbidities, 21.4% with
CV diseases and 11.5% with renal conditions [11].






Anti-hypertensive drug, n (%)
All drugsa 2141 (71%) 4082 (71%)
Diuretic 1704 (80%)b 3339 (82%)b
ACE-I 1113 (52%)b 2180 (53%)c
Calcium channel blocker 1081 (50%)b 1773 (43%)c
ARB 914 (43%)b 1723 (42%)c
Any other drugs 53 (2%)b 102 (2%)c
ACE-I: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor
blocker, MM: multiple myeloma
aAll anti-hypertensive drugs included diuretics, ACE-I, ARBs, calcium channel
blockers and other (alpha blockers, alpha-2 receptor agonists, beta-blockers,
central agonists, combined alpha and beta blockers, peripheral adrenergic in-
hibitors, renin inhibitors and vasodilators)
bPercentage derived from n = 2141 MM patients treated for hypertension
cPercentage derived from n = 4082 non-MM patients treated for hypertension
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and renal failure is a negative prognostic factor for pa-
tient survival [5]. In this study, renal failure at the start
of treatment in patients without a history of baseline
hypertension did appear to be a risk factor for hyperten-
sion during treatment; however, patients were only at
risk for malignant hypertension if renal failure was also
associated with baseline hypertension.
Hypertension has been reported to be twice as fre-
quent in patients with diabetes than in those without
diabetes [12]. The findings from this study also show
close to double the rate of hypertension in non-MM pa-
tients with diabetes (54%) versus those without diabetesFig. 4 Addition of anti-hypertensive medications during the follow-up period
added included diuretics, ACE-I, angiotensin II blockers, calcium channel block
central agonists, combined alpha and beta blockers, peripheral adrenergic inh
enzyme inhibitor; MM, multiple myeloma(30%) (data not shown). For MM patients, the rate of
hypertension was 54% in those with co-existing diabetes
and 36% in patients without diabetes (data not shown).
This is of particular concern given that the routine use
of corticosteroids in myeloma therapy can lead to new
diagnoses of diabetes or worsen glycemic control of
those with known diabetes. Taken together, these results
show that control and prevention of hypertensive events
in MM patients must include management of CV
comorbidities.
Per the 8th Joint National Committee of 2014 evidence-
based guidelines for management of high blood pressure
in adults, “hypertension is one of the most important pre-
ventable contributors to disease and death” [13]. The
guidelines recommend initiating drug treatment in non-
black hypertensive patients with an ACE-I, ARB, calcium
channel blocker or thiazide-type diuretic; in black hyper-
tensive patients, initial therapy should include a calcium
channel blocker or thiazide-type diuretic. The most com-
mon anti-hypertensive medications at baseline for this
study were diuretics, ACE-I, calcium channel blockers and
ARBs. For patients with a history of hypertension, the
same percentage of patients (71%) in the MM and non-
MM groups were receiving anti-hypertensive medications,
as well as similar numbers of anti-hypertensive medica-
tions at baseline. During the follow-up period, similar per-
centages were seen between the MM patients and non-
MM patients with incident hypertension.
The choice of anti-hypertensive therapy in a myeloma
patient, however, must take into account myeloma-
associated renal failure (hence caution with diuretics and
ACE-I/ARB), hypercalcemia or hyperuricemia (whichfor MM and non-MM patients. Classes of anti-hypertensive medications
ers and other (alpha blockers, alpha-2 receptor agonists, beta-blockers,
ibitors, renin inhibitors and vasodilators). ACE-I, angiotension-converting
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(which can be exacerbated by calcium channel blockers). It
should also be noted that grade 3 hypertension in clinical
trials does not necessarily equate to markedly elevated
blood pressures or malignant hypertension, as the addition
of blood pressure medications is considered a grade 3
hypertension adverse event per National Cancer Institute
Common Toxicity Criteria definition. Addition of anti-
hypertensive medications was not included as a hyperten-
sive event in this study; however, evaluation of anti-
hypertensive medications in the follow-up period found ap-
proximately 6% more MM patients than non-MM patients
had one class of anti-hypertensive medication added.
The results of this study emphasize that CV and
hypertensive adverse effects cannot be evaluated in clini-
cal trials without a comparator arm, given the high inci-
dence rates of these complications in MM patients. MM
patients entering the trials are already at a high risk for
hypertensive events, and existing hypertension is a
major risk factor for development of malignant hyper-
tension. Hypertension has been reported as an adverse
event in studies of patients undergoing MM treatment
[5–7, 14–18].
Although this study evaluated hypertension and malig-
nant hypertension in MM patients undergoing treatment
for MM, it did not evaluate results for specific anti-
myeloma treatments. There are some other limitations
of this study. MarketScan claims database better repre-
sents the demographic distribution of employed popula-
tions while under-representing the elderly, unemployed
and disabled. This may be a reason why the median age
of MM diagnosis in this study, 65 years, was close to,
but a little younger than that published in the literature
for median age of MM incidence (69 years SEER cancer
statistics) [2]. The MarketScan database does not include
information about race, precluding examining the effect of
race on these findings (for example, hypertension rates in
black vs. white patients, since MM is two-fold more com-
mon than in white patients) [2]. In addition, survival data
and hypertension and other CV co-morbidity risk factors
such as obesity, diet, physical activity and smoking status
are not included in the database. There exists the possibil-
ity that malignant hypertension may be underestimated in
MM patients for whom hospital admissions were not ex-
plicitly coded as such, due to the presence of other acute
medical issues such as disease progression. Finally, this
study could not control for ascertainment bias; MM pa-
tients under treatment would be evaluated more fre-
quently by physicians than non-MM patients and thus
have a higher probability of hypertensive events reported.
Conclusion
The incidence of hypertension and malignant hyperten-
sion is significantly higher in newly-treated MM patientscompared with non-MM patients. Hypertension is a risk
factor for MM patients developing malignant hyperten-
sion. The presence of hypertension and co-existing car-
diomyopathy, renal failure or diabetes also significantly
increase the risk of MM patients developing malignant
hypertension. Due to the introduction of novel effica-
cious agents that will likely improve life expectancy,
more MM patients will be living longer and will likely be
at a greater risk of developing CV complications. The
findings of this study highlight the need for a multi-
disciplinary approach in managing MM, especially in
elderly patients at a greater risk of CV events. A close
collaboration between oncologists, cardiologists, ne-
phrologists and primary care physicians is warranted.
Additional file
Additional file 1: Table S1. Comorbidity ICD-9 codes. ICD-9, International
Classification of Diseases, ninth revision. (DOCX 25 kb)
Abbreviations
ACE-I: Angiotensin-converting enzyme inhibitor; ARB: Angiotension II
receptor blocker; CCI: Charlson comorbidity index; CI: Confidence interval;
CV: Cardiovascular; HIPAA: Healthcare Information Portability and
Accountability Act; HR: Hazard ratio; ICD-9: International Classification of
Diseases, Revision 9; MM: Multiple myeloma; PYR: Person year; SD: Standard
deviation; US: United States
Acknowledgements
ARL is supported by the National Institute of Health Research Cardiovascular
Biomedical Research Unit at the Royal Brompton Hospital and the British
Heart Foundation (FS/11/67/28954).
Funding
Financial support for this study was provided by Amgen, Inc., South San
Francisco, CA. Medical writing assistance was provided by BlueMomentum, an
Ashfield Company, part of UDG Healthcare PLC, and funded by Amgen, Inc.
Availability of data and materials
The data that support the findings of this study are available from Truven
Health Analytics but restrictions apply to the availability of these data, which
were used under license for the current study, and so are not publicly
available. Data are however available from the authors upon reasonable
request and with permission of Truven Health Analytics.
Authors’ contributions
AC, AL, KM, DF and WW: conception and design of the study. DF, SZ and
WW: acquisition of data and data analysis. All authors participated in data
interpretation, have been involved in drafting the manuscript or revising it
critically for important intellectual content, have provided final approval of
the version to be published, and agree to be accountable for all aspects of
the work.
Competing interests
AC has served as a consultant for and received research funding from
Janssen Pharmaceutical and Bristol-Myers Squibb, and has received research
funding and honoraria from Takeda, Celgene, Array BioPharma, Novartis and
Onyx Pharmaceuticals. ARL has served as a consultant for Onyx Pharmaceuticals.
KM, SZ and WW are employees of Amgen Inc. DF is an employee of Onyx
Pharmaceuticals, Inc., an Amgen subsidiary.
Consent for publication
Not applicable.
Chari et al. BMC Cancer  (2016) 16:912 Page 10 of 10Ethics approval and consent to participate
Ethics approval was not applicable to this study. Given the de-identified nature
of the claims data used in this study, informed consent was not required by
HIPAA rules. Reporting of individual person data was not applicable in this
study.
Author details
1Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York,
NY, USA. 2Amgen Inc., One Amgen Center Dr, Thousand Oaks, CA, USA.
3Simulstat, Inc., 4370 La Jolla Village Dr, San Diego, CA, USA. 4Amgen Inc.,
1120 Veterans Blvd, South San Francisco, CA, USA. 5Onyx Pharmaceuticals,
Inc., an Amgen subsidiary, 1641 Kansas St, Redwood City, CA, USA. 6NIHR
Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and
Imperial College London, SW3 6NP, London, UK.
Received: 15 July 2016 Accepted: 10 November 2016References
1. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C,
et al. NCCN Guidelines insights: Multiple myeloma, Version 3.2016. J Natl
Compr Canc Netw. 2016;14(4):389–400.
2. SEER Cancer Statistics Factsheets. Myeloma. Bethesda: National Cancer
Institute. http://seer.cancer.gov/statfacts/html/mulmy.html.
Accessed 11 Feb 2016.
3. Strait JD, Lakatta EG. Aging-associated cardiovascular changes and their
relationship to heart failure. Heart Fail Clin. 2012;8(1):143–64.
4. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity
derived from ICD-9-CM administrative data. Med Care. 2002;40:675–85.
5. Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of
patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):
827–35.
6. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple
myeloma. N Engl J Med. 2015;372(2):142–52.
7. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a
randomized phase 2 study of bevacizumab and bortezomib versus bortezomib
in relapsed or refractory multiple myeloma. Cancer. 2013;119:339–47.
8. Kistler KD, Murphy B, Kalman J, Sahni G, Werther W, Rajangam K, et al. A
comparison of cardiac event rates in patients with or without multiple
myeloma in the United States. J Clin Oncol. 2014;32:e19563.
9. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the US:
National Health and Nutrition Examination Survey, 2011–2012. NCHS Data
Brief, No. 133. Hyattsville: National Center for Health Statistics, Centers for
Disease Control and Prevention, US Dept of Health and Human Services; 2013.
10. Wong ND, Lopez VA, Italien GL, Chen R, Kline SEJ, Franklin SS. Inadequate
control of hypertension in US adults with cardiovascular disease
comorbidities in 2003–2004. Arch Intern Med. 2007;167(22):2431–36.
11. Chen YJ, De AP, Cong Z, Aggarwal SK, Wade RL. Demographic and
comorbidity characteristics of newly diagnosed multiple myeloma patients
in the United States: A real world data analysis. Blood. 2014;124(21):1301.
12. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and
cardiovascular disease. An update. Hypertension. 2001;37:1053–9.
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C,
Handler J, et al. 2014 Evidence-based guidelines for the management of
high blood pressure in adults. Report from the panel members appointed
to the Eighth Joint National Committee (JNC8). JAMA. 2014;311(5):507–20.
14. Oshikawa G, Kojima A, Doki N, Kobayashi T, Kakihana K, Tsuda H, et al.
Bortezomib-induced posterior reversible encephalopathy syndrome in a
patients with newly diagnosed multiple myeloma. Intern Med. 2013;52:111–14.
15. Yang S, Jun M, Hong-Li Z, Jian-Min W, Chun W, Lu-Gui Q, et al. A multi-
center open-labeled study of recombinant erythropoietin-beta in the
treatment of anemic patients with multiple myeloma, low-grade non-
Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese
population. Int J Hematol. 2008;88(2):139–44.
16. Zhao Y, Jing Y, Bo J, Li HH, Wang SH, Huang WR, et al. Adverse effects of
PAD and VAD regimens in multiple myeloma patients. [Article in Chinese]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18(4):1027–30.17. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for
patients with relapsed or refractory multiple myeloma (ENDEAVOR): a
randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;
17(1):27–38.
18. Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, et al.
Phase I study of 30-minute infusion of carfilzomib as single agent or in
combination with low-dose dexamethasone in patients with relapsed and/
or refractory multiple myeloma. J Clin Oncol. 2015;33(7):732–9.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
